{"id":"W4327898108","doi":"10.1093/ecco-jcc/jjad047","title":"A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease","year":2023,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Janssen Research and Development; Allergan; Genentech; Celltrion; UCB Pharma; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Celgene; Biogen; EA Pharma Co., Ltd.; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Tillotts Pharma; Amgen; Kyorin Pharmaceutical; Pfizer; Sanofi; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Medicine; Crohn's disease; Placebo; Double blind; Physical therapy; Multicenter study; Disease; Surgery; Internal medicine; Randomized controlled trial; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003647412,0.00221827,0.003272034,0.0005792509,0.0006943716,0.0009790045,0.001051728,0.002204709,0.005641052],"category_scores_gemma":[0.002539339,0.001109323,0.001448142,0.000537649,0.001559332,0.001195016,0.0004601978,0.002893342,0.001091598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006887525,"about_ca_system_score_gemma":0.001773783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006201412,"about_ca_topic_score_gemma":0.001254061,"domain_scores_codex":[0.9989163,0.0006261692,0.00006920926,0.0001789572,0.00008456518,0.000124847],"domain_scores_gemma":[0.9983424,0.0003111151,0.000376854,0.0001463199,0.0001420712,0.0006811626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9598557,0.01800275,0.001318689,0.0004492484,0.0005183788,0.00006389591,0.0001085647,0.0002469533,0.008571992,0.00007389998,0.0007130041,0.01007696],"study_design_scores_gemma":[0.9202684,0.0768977,0.001762385,0.000009716608,0.0001504175,0.00003432189,0.00001100834,0.0001210118,0.000310249,0.00003636572,0.0003894302,0.000009054518],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835377,0.002614672,0.0009357905,0.0007371777,0.0003452143,0.008952654,0.001398265,0.0001088597,0.001369732],"genre_scores_gemma":[0.9699016,0.002116193,0.004267127,0.00214629,0.0006403505,0.01521709,0.002661692,0.00004339091,0.003006271],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005641052,"threshold_uncertainty_score":0.01928961,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01831936520962939,"score_gpt":0.3092495554112838,"score_spread":0.2909301902016544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}